- Email: [email protected]
Gemcitabine Therapy in Patients with Pancreatic Cancer
Annals of Oncology 25 (Supplement 5): v75–v109, 2014 doi:10.1093/annonc/mdu436.136
Poster Session (Poster presentations categorized by each organ) P3
12
4
abstracts
Shigeru Tanaka1, Tomoya Shimokata2, Hiroaki Tsukuura2, Osamu Maeda2, Ayako Mitsuma2, Eizaburo Ohno3, Hiroki Kawashima4, Yoshiki Hirooka3, Hidemi Goto3,4, Yuichi Ando2 1 Department of General Medicine, Okazaki City Hospital 2 Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital 3 Department of Endoscopy, Nagoya University Hospital 4 Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v105/2240409 by guest on 26 October 2019
INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ERLOTINIB/GEMCITABINE THERAPY IN PATIENTS WITH PANCREATIC CANCER
Background: Erlotinib (ERL)/gemcitabine (GEM) therapy is an approved standard chemotherapy for advanced pancreatic cancer. The prevalence and risk factors of interstitial lung disease (ILD) associated with this treatment in a real-world population remain uncertain. Methods: We retrospectively reviewed medical records of patients with pancreatic cancer who received GEM/ERL therapy at Nagoya University Hospital. Results: Among 19 patients (M/F, 12/7) who received the GEM/ERL therapy between July 2011 and November 2013, we identified 4 (21%) patients who experienced drug-associated ILD (grade, 1/1/2/3; F/M/M/M; PS 0/1/0/1; ages at the diagnosis, 62/ 62/70/44 years old; Brinkman index (BI), 0/600/1,000/270, respectively). Pulmonary toxicity of grade 1 was observed in 2 patients, and grade 2 and grade 3 in one patient each. Chest CT scan at baseline did not show any interstitial shadows in all 4 patients, and the time to the onset of ILD after starting the treatment was 5, 18, 77, and 12 weeks, respectively. The patient with grade 3 ILD (44-year-old male, PS 1, BI of 270, 12 weeks after starting treatment at onset) was successfully treated with intravenous pulse steroid therapy, and the other 3 patients with grade 1 or 2 ILD fully recovered just by suspending GEM/ERL therapy. Conclusion: The prevalence of ILD among the patients who received GEM/ERL therapy in a real-world population was higher than that of the JO20302/JO21097 trial (8.5%). Smoking status would be an ILD risk factor.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Poster Session (Poster presentations categorized by each organ) P3
12
4
abstracts
Shigeru Tanaka1, Tomoya Shimokata2, Hiroaki Tsukuura2, Osamu Maeda2, Ayako Mitsuma2, Eizaburo Ohno3, Hiroki Kawashima4, Yoshiki Hirooka3, Hidemi Goto3,4, Yuichi Ando2 1 Department of General Medicine, Okazaki City Hospital 2 Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital 3 Department of Endoscopy, Nagoya University Hospital 4 Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v105/2240409 by guest on 26 October 2019
INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ERLOTINIB/GEMCITABINE THERAPY IN PATIENTS WITH PANCREATIC CANCER
Background: Erlotinib (ERL)/gemcitabine (GEM) therapy is an approved standard chemotherapy for advanced pancreatic cancer. The prevalence and risk factors of interstitial lung disease (ILD) associated with this treatment in a real-world population remain uncertain. Methods: We retrospectively reviewed medical records of patients with pancreatic cancer who received GEM/ERL therapy at Nagoya University Hospital. Results: Among 19 patients (M/F, 12/7) who received the GEM/ERL therapy between July 2011 and November 2013, we identified 4 (21%) patients who experienced drug-associated ILD (grade, 1/1/2/3; F/M/M/M; PS 0/1/0/1; ages at the diagnosis, 62/ 62/70/44 years old; Brinkman index (BI), 0/600/1,000/270, respectively). Pulmonary toxicity of grade 1 was observed in 2 patients, and grade 2 and grade 3 in one patient each. Chest CT scan at baseline did not show any interstitial shadows in all 4 patients, and the time to the onset of ILD after starting the treatment was 5, 18, 77, and 12 weeks, respectively. The patient with grade 3 ILD (44-year-old male, PS 1, BI of 270, 12 weeks after starting treatment at onset) was successfully treated with intravenous pulse steroid therapy, and the other 3 patients with grade 1 or 2 ILD fully recovered just by suspending GEM/ERL therapy. Conclusion: The prevalence of ILD among the patients who received GEM/ERL therapy in a real-world population was higher than that of the JO20302/JO21097 trial (8.5%). Smoking status would be an ILD risk factor.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].